ProtoKinetix
(OTCQB:PKTX) (www.protokinetix.com)
today announced that Peter K. Jensen, LL.B., BCL, B.Sc., Chairman of
RepliCel Life Sciences and practicing lawyer, was appointed to the
company’s board of directors. The Company has also issued 1,000,000
shares of common stock of the Company and a three-year option for
1,000,000 shares of common stock exercisable at $0.05US per share to Mr.
Jensen in connection with his appointment to the Board and for services
to the Company.
“Peter has extraordinary biotechnology and business expertise, and we
are delighted that he is joining ProtoKinetix’s board of directors,”
said Clarence Smith, ProtoKinetix Chairman.
About Peter Jensen
Mr. Jensen is married with five children. He acquired his Bachelor of
Science and Law degrees at McGill University in Montreal, Quebec, with a
dual degree in common and civil law. His science degree is in the field
of biology (marine biology and ecology). He also conducted diabetes
research at the Royal Victoria Hospital (Montreal), was a director of a
community medical clinic for three years and ran the McGill legal clinic
for two years.
In 1981 Mr. Jensen commenced the practice of law in the corporate and
securities fields in British Columbia. Mr. Jensen has a wide range of
legal counseling experience internationally. Mr. Jensen has an
understanding of the particular nature of the challenges facing
corporate management as he has been and is a director of a number of
private and publicly traded companies, has been a board member of
companies with capitalization in the hundreds of millions and has
assisted in the raising of capital in ranges of up to one hundred
million dollars in Canada, the United States, Europe, and the Orient.
In addition to continuing an active legal practice at Beadle Raven LLP,
Mr. Jensen is Chairman of RepliCel Life Sciences. RepliCel is a publicly
listed cell replication company which recently struck an agreement with
Shiseido of Japan to license Shiseido with RepliCel’s leading edge cell
replication technology. Mr. Jensen is Chairman of Solar Flow-Through
Limited Partnerships I, II, III and IV which are installing solar power
arrays in Ontario under the Ontario FIT program. Mr. Jensen is also a
director of a British Columbia public agricultural land banking company,
New Age Farms, and of a California public company, bBooth Inc, offering
music booth recording facilities to the public.
About ProtoKinetix
ProtoKinetix, Inc. is a molecular biotechnology company that has
developed and patented a family of hyper stable, potent glycopeptides
(AAGP™). These molecules have been demonstrated to protect cells against
hostile conditions that are present in all areas of transplantation
including regenerative medicine.
The Private Securities Litigation Reform Act of 1995 provides a “safe
harbor” for forward-looking statements. Some information included in
this press release contains statements that are forward-looking. Such
forward-looking information involves significant risks and uncertainties
that could affect anticipated results in the future and, accordingly,
these results may differ materially from those expressed in any
forward-looking statements made by or on behalf of the Company. For a
description of additional risks and uncertainties, please refer to the
Company’s filings with the Securities and Exchange Commission.
Clarence E. Smith – President and CEO
Copyright Business Wire 2015